Totarol

Totarol

SCHEMBL30105648

CC(C)c1c(O)ccc2c1CC[C@@H]1C(C)(C)CCC[C@]21C

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 5/20 1.00
▸ MAPT P10636 4/20 1.00
▸ USP2 O75604 4/20 1.00
▸ TP53 P04637 4/20 1.00
▸ MEN1 O00255 3/20 1.00
▸ KMT2A Q03164 3/20 1.00
▸ MAPK1 P28482 2/20 1.00
▸ HSP90AA1 P07900 1/20 1.00
▸ KDM4E B2RXH2 1/20 1.00
▸ HPGD P15428 1/20 0.74
▸ ALOX15 P16050 1/20 0.74
▸ SMN1; SMN2 Q16637 1/20 0.69
▸ PIP5K1A Q99755 4/20 0.50
▸ CYP19A1 P11511 1/20 0.50
▸ CSNK2A2 P19784 2/20 0.48
▸ CSNK2B P67870 2/20 0.48
▸ CSNK2A1 P68400 2/20 0.48
▸ CSNK2A3 Q8NEV1 2/20 0.48
▸ CETP P11597 3/20 0.45
▸ KARS1 Q15046 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Totarol SCHEMBL16238019 1.00 CYP3A4 (1.00) CYP3A4MAPTUSP2TP53MEN1
Totarol SCHEMBL13423504 1.00 CYP3A4 (1.00) CYP3A4MAPTUSP2TP53MEN1
Totarol SCHEMBL285501 1.00 CYP3A4 (1.00) CYP3A4MAPTUSP2TP53MEN1
Totarol SCHEMBL31121504 1.00 CYP3A4 (1.00) CYP3A4MAPTUSP2TP53MEN1
Totarol SCHEMBL1839596 1.00 CYP3A4 (1.00) CYP3A4MAPTUSP2TP53MEN1
19-Hydroxytotarol SCHEMBL13423507 0.85 CYP3A4 (1.00) CYP3A4MAPTUSP2TP53MEN1
19-Hydroxytotarol SCHEMBL12998342 0.85 CYP3A4 (1.00) CYP3A4MAPTUSP2TP53MEN1
Totarol SCHEMBL31287563 0.85 CYP3A4 (0.74) CYP3A4MAPTUSP2TP53MEN1
SCHEMBL5522477 0.84 CYP3A4 (0.78) CYP3A4MAPTUSP2TP53MEN1
SCHEMBL20970940 0.84 USP2 (0.82) CYP3A4MAPTUSP2TP53MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260034186-A1 ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS RIZUN NODARI (US) 2026-02-05 — — US disclosed
US-20260027136-A1 CANNABIS BASED THERAPEUTIC AND METHOD OF USE YUZU LV LLC (US) 2026-01-29 — — US disclosed
US-12458653-B2 Cannabis based therapeutic and method of use YUZU LV LLC (US) 2025-11-04 — — US disclosed
US-12427176-B2 Enriched mineral pitch resin products and methods of manufacturing enriched mineral pitch resin products RIZUN NODARI (US) 2025-09-30 — — US disclosed
US-12303488-B2 Cannabis based therapeutic and method of use YUZU LV LLC (US) 2025-05-20 — — US disclosed
EP-4417252-A2 CANNABIS BASED THERAPEUTIC AND METHOD OF USE Yuzu LV LLC (US) 2024-08-21 — — EP disclosed
US-20240216456-A1 ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS RIZUN NODARI (US) 2024-07-04 — — US disclosed
US-20240216457-A1 ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS RIZUN NODARI (US) 2024-07-04 — — US disclosed
US-20240207344-A1 ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS RIZUN NODARI (US) 2024-06-27 — — US disclosed
US-20240207342-A1 ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS RIZUN NODARI (US) 2024-06-27 — — US disclosed
US-20240108676-A1 ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS RIZUN NODARI (US) 2024-04-04 — — US disclosed
US-11883454-B2 Enriched mineral pitch resin products and methods of manufacturing enriched mineral pitch resin products RIZUN NODARI (US) 2024-01-30 — — US disclosed
US-20230405067-A1 ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS RIZUN NODARI (US) 2023-12-21 — — US disclosed
US-20230346739-A1 CANNABIS BASED THERAPEUTIC AND METHOD OF USE YUZU LV LLC 2023-11-02 — — US disclosed
US-20230293480-A1 CANNABIS BASED THERAPEUTIC AND METHOD OF USE YUZU LV LLC 2023-09-21 — — US disclosed
US-20230293555-A1 COMPOSITIONS COMPRISING CANNABIDIOL AND FLAVANONES YUZU LV LLC 2023-09-21 — — US disclosed
US-11684604-B2 Cannabis based therapeutic and method of use YUZU LV LLC (US) 2023-06-27 — — US disclosed
US-20220387537-A1 ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS RIZUN NODARI (US) 2022-12-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11684604-B2 Cannabis based therapeutic and method of use CNR2, CNR1, OPRK1 CYP3A4 2613/4885MAPT 990/4885USP2 1798/4885
US-20260027136-A1 CANNABIS BASED THERAPEUTIC AND METHOD OF USE CNR1, CNR2, OPRM1 CYP3A4 1136/4885MAPT 719/4885USP2 4554/4885
US-20260034186-A1 ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS TRPV1, SOST, RUNX1 CYP3A4 1979/4885MAPT 37/4885USP2 4459/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback